<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930887</url>
  </required_header>
  <id_info>
    <org_study_id>60832</org_study_id>
    <nct_id>NCT04930887</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain</brief_title>
  <official_title>Prospective, Randomized, Double-blinded, Placebo-controlled, Cross-over Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) Towards the Ipsilateral Pterygopalatine Fossa for the Treatment of Craniofacial Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose&#xD;
      administration at surgical sites. The study aims to evaluate the effectiveness of&#xD;
      endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial&#xD;
      pain. This study would be conducted in a prospective, randomized, double-blinded, placebo-&#xD;
      controlled, and cross-over fashion. We aim to investigate whether the administration of&#xD;
      Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and&#xD;
      functional outcomes, in patients who experience relief with the topical application of&#xD;
      Lidocaine (routinely given prior to almost all ENT endoscopy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pain Score</measure>
    <time_frame>Baseline to day 21</time_frame>
    <description>Scores range from 0-10 (0=no pain, 10=worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Associated Symptoms</measure>
    <time_frame>Baseline to day 21</time_frame>
    <description>Changes of associated symptoms, including nausea, photophobia, use of rescue medication, relapse of headache, and/or change in headache disability scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Craniofacial Pain</condition>
  <condition>Migraine</condition>
  <condition>Cluster Headache</condition>
  <condition>Trigeminal Autonomic Cephalgia</condition>
  <condition>Sphenopalatine Ganglion Neuralgia</condition>
  <condition>Paroxysmal Hemicrania</condition>
  <arm_group>
    <arm_group_label>Exparel, Then Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received an endoscopically guided injection of Exparel (Bupivacaine). After 3 weeks they then received Placebo treatment (Saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline, Then Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Placebo treatment (Saline). After 3 weeks they then received an endoscopically guided injection of Exparel (Bupivacaine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel (Bupivacaine Liposome)</intervention_name>
    <description>Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally</description>
    <arm_group_label>Exparel, Then Saline</arm_group_label>
    <arm_group_label>Saline, Then Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment</description>
    <arm_group_label>Exparel, Then Saline</arm_group_label>
    <arm_group_label>Saline, Then Exparel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a chief complaint of craniofacial pain (migraine, cluster headache,&#xD;
             trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmal&#xD;
             hemicrania) who has Stanford Pain &amp; ENT clinic visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18 or &gt;80&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  economically disadvantaged (not able to afford clinic visits/treatments)&#xD;
&#xD;
          -  decisionally impaired (unable to obtain informed consent)&#xD;
&#xD;
          -  has allergy to bupivacaine&#xD;
&#xD;
          -  unable or unwilling to participate plans to participate in another clinical study at&#xD;
             any time during this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Lechner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matt Lechner, MD, PhD</last_name>
    <phone>(650) 723-5281</phone>
    <email>mlechner@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Peter Hwang</investigator_full_name>
    <investigator_title>PROFESSOR OF OTOLARYNGOLOGY - HEAD &amp; NECK SURGERY (OHNS) AND, BY COURTESY, OF NEUROSURGERY AT THE STANFORD UNIVERSITY MEDICAL CENTER</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Trigeminal Autonomic Cephalalgias</mesh_term>
    <mesh_term>Paroxysmal Hemicrania</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be kept confidential and private and won't be used for any other studies or shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

